Search Results - "Richarz, Nina"

Refine Results
  1. 1

    PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression by Kraft, Stefan, Fernandez-Figueras, Maria-Teresa, Richarz, Nina A., Flaherty, Keith T., Hoang, Mai P.

    “…The prognostic role of programmed death ligand 1 (PDL1), CD8, and forkhead box p3 (FoxP3) expression in desmoplastic melanomas is unclear. We correlated PDL1,…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Challenges for New Adopters in Pre-Surgical Margin Assessment by Handheld Reflectance Confocal Microscope of Basal Cell Carcinoma; A Prospective Single-center Study by Richarz, Nina Anika, Boada, Aram, Jaka, Ane, Bassas, Julio, Ferrándiz, Carlos, Carrascosa, José Manuel, Yélamos, Oriol

    Published in Dermatology practical & conceptual (01-10-2022)
    “…In vivo reflectance confocal microscopy (RCM) is a useful tool for assessing pre-surgical skin tumor margins when performed by a skilled, experienced user. The…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma: a Spanish center's decade of experience by Sun, Chen, España, Sofia, Richarz, Nina, Solé-Blanch, Carme, Boada, Aram, Martinez-Cardús, Anna, Chu, Alan, Liu, Zongwen, Manzano, Jose Luis

    Published in Frontiers in oncology (21-02-2024)
    “…Targeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis by Richarz, Nina Anika, Puig, Luis, Pérez, Noelia, Cuadra-Urteaga, Jose, Elez, Elena, Fernández-Figueras, Maria Teresa

    Published in Cancer biology & therapy (2019)
    “…Neutrophilic panniculitis is an infrequent but characteristic adverse event under therapy with BRAF inhibitors (BRAFi). Since the approval of vemurafenib for…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20